AMBROXOL (EG)*soluz nebul 10 vials 15 mg 2 ml

Name
AMBROXOL EG 15 MG/2 ML NEBULIZER SOLUTION

Active ingredients
AMBROXOL EG 15 mg/2 ml Solution for nebulization One vial contains: Active ingredient : ambroxol hydrochloride 15 mg. For the full list of excipients, see section 6.1.

Therapeutic indications
Treatment of secretion disorders in acute and chronic bronchopulmonary diseases.

Dosage
The following dosages are recommended unless otherwise prescribed by your doctor: Adults: 2-3 vials per day. Children over 5 years: 2-3 vials per day. Children up to 5 years: 1-2 vials per day. Since deep breathing from aerosols can cause coughing, try to breathe normally during inhalation. It is recommended to warm the solution to body temperature before inhalation. In patients with bronchial asthma, it is recommended to administer a standard bronchospasmolytic before inhalation. The nebulized solution can be administered using standard aerosol therapy devices. It can also be diluted in distilled water in a 1:1 ratio. Do not use ambroxol for prolonged treatments.

Conservation
This medicinal product does not require any special storage conditions.

Pregnancy and breastfeeding
Pregnancy: Ambroxol hydrochloride crosses the placental barrier. Animal studies do not indicate direct or indirect harmful effects on pregnancy, embryonic/fetal development, parturition, or postnatal development (see section 5.3). Although preclinical studies and extensive clinical experience have not revealed any harmful effects after the 28th week of gestation, it is advisable to follow the usual precautions when taking medications during pregnancy. Taking Ambroxol EG is not recommended, especially during the first trimester. Caution should be exercised when prescribing the medicine to pregnant women. Medicines should be prescribed during pregnancy only if the expected benefit to the mother is considered to outweigh the risk to the fetus. All medications should be avoided, if possible, during the first trimester of pregnancy. Breastfeeding Ambroxol hydrochloride is excreted in breast milk. Although no adverse effects on breastfed children are expected, the use of AMBROXOL EG is not recommended in breastfeeding mothers.